Publications by authors named "James A Davis"

Claim this Profile
P
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Rahul Banerjee, Gurbakhash Kaur, Beatrice M Razzo, Andrew J Portuguese, Surbhi Sidana, James A Davis

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis.
Matthew J Rees, Jack Khouri, Ariel F Grajales-Cruz, Saurabh S Zanwar, Utkarsh Goel, James A Davis

Am J Hematol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure.
Prerna Mewawalla, Rachel Dileo, Yue Yin, Christopher Strouse, Hira Shaikh, James A Davis

Clin Lymphoma Myeloma Leuk· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
Gliceida M Galarza Fortuna, Lauren Peres, Elena Nazarenko, Andre De Menezes Silva Corraes, Vanna N Hovanky, James A Davis

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.
Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes, James A Davis

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, Narendranath Epperla, Deborah M Stephens, James A Davis

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.
Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, James A Davis

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.
Binod Dhakal, Othman S Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, James A Davis

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium.
Megan Melody, Natalie S Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese, James A Davis

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.
Brian Hess, Alison Moskowitz, James A Davis, Paolo Strati, Yazeed Sawalha

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.
Anas Zayad, Gray Magee, Razan Mansour, Mark Chang, Nausheen Ahmed, James A Davis

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.
Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F Grajales-Cruz, Jack Khouri, James A Davis

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson

Bone Marrow Transplant· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.
Nicole J Altomare, Megan M Herr, Nisha M Nair, Deborah M Stephens, Jonathon B Cohen, James A Davis

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Danai Dima, Mariola A Vazquez-Martinez, James A Davis, Utkarsh Goel, Aimaz Afrough

Blood Cancer J· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, James A Davis

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, James A Davis

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.
Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A Davis

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune, James A Davis

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.
Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse, James A Davis

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, James A Davis

Blood Cancer J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of the OsWRKY71 transcription factor gene results in early rice seed germination under normal and cold stress conditions.
Santiago Bataller, James A Davis, Lingkun Gu, Sophia Baca, Gaelan Chen

BMC Plant Biol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.
William Wesson, Danai Dima, Nahid Suleman, Md Saiful Islam Saif, Carine Tabak, James A Davis

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
:
: A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma.
Kevin C Graf, James A Davis, Alyssa Cendagorta, Katelynn Granger, Kelly J Gaffney

EJHaem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis